Clinical trial NCT01012479: Efficacy and Safety of Candesartan Cilexetil Plus Hydrochlorothiazide in Subjects With Severe Hypertension
Official title: Clinical Study to Evaluate the Efficacy and Safety of the Combination Therapy Candesartan Cilexetil 32 mg Plus Hydrochlorothiazide 25 mg in Patients With Severe Hypertension
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Hypertension
Keywords: Blood Pressure
Blood Pressure, High
Drug Therapy
Lead sponsor: Takeda
Sponsor class: INDUSTRY
First posted: 2009-11-13
Enrollment: 107
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to see if Candesartan, once daily (QD), added with Hydrochlorothiazide may be helpful in treating people with newly diagnosed severe essential hypertension.

Detailed description: Medical data show a link between blood pressure and the risk of heart disease (cardiovascular disease) such as stroke and heart attack. Clinical trials have shown that lowering blood pressure in patients with high blood pressure (hypertension) reduces the number of cardiovascular events.

Many people still have untreated hypertension. There are many reasons why target blood pressure is not reached. One is that most patients need more than one antihypertensive drug in order to lower high blood pressure. Other reasons include poor patient compliance with taking their drugs.

Combining drugs that lower high blood pressure and have similar ways of working in the body may help high blood pressure and lower the risk for medication-related side effects. One of several drug combinations recommended for the treatment of high blood pressure is an angiotensin receptor blocker and a thiazide diuretic. Guidelines also note that combination tablets may improve patient compliance with taking their drugs.

Candesartan is an angiotensin type-1 receptor blocker. Hydrochlorothiazide is a diuretic with blood pressure-lowering effect. This study will combine both of these drugs in one pill and see how it works in people taking part in this study.

Eligibility criteria: Inclusion Criteria:

* Confirmed diagnosis of essential hypertension.
* Has Systolic Blood Pressure between 150 mmHg and 200 mmHg AND Diastolic Blood Pressure between 110 mmHg and 120 mmHg.
* Has not received any antihypertensive treatment so far.
* Has a negative pregnancy test at baseline in females of childbearing potential. Male and female participants with reproductive potential must use an approved contraceptive method during study treatment evaluation

Exclusion Criteria:

* Has a known or suspected secondary hypertension or primary hyperaldosteronism.
* Has impaired renal function.
* Has severe hepatic impairment.
* Has bilateral renal artery stenosis, solitary kidney or post-renal transplant status.
* Has a history of myocardial infarction, coronary artery bypass graft, percutaneous coronary intervention or cerebral accident (stroke or transient ischaemic attack) within the last 6 months.
* Has a diagnosis or suspicion of the following conditions: hypertrophic obstructive cardiomyopathy, angina pectoris, chronic heart failure, peripheral arterial occlusive disease, hypertensive retinopathy.
* Has hemodynamically relevant stenosis of the aortic or mitral valve.
* Has clinically relevant and refractory hypokalaemia or hyperkalaemia.
* Has uncorrected volume or sodium depletion.
* Has gout or relevant hyperuricaemia.
* Has a known intolerance/hypersensitivity to Candesartan cilexetil or Hydrochlorothiazide.
* Has a known galactose intolerance, lactase deficiency or glucose-galactose malabsorption.
* Is taking psychotropic medication or is addicted to alcohol or drugs.
* Has participated in another trial of an investigational drug or a medical device within the last 30 days or is currently participating in another trial of an investigational drug or a medical device.

Primary outcomes:
measure: Change from Baseline in Systolic Blood Pressure at Week 9.
timeFrame: Baseline and Week 9.
measure: Change from Baseline in Diastolic Blood Pressure at Week 9.
timeFrame: Baseline and Week 9.
Secondary outcomes:
measure: Percentage of subjects showing a decrease in SBP to less than 140 mmHg and/or a decrease of SBP by at least 20 mmHg AND a decrease in DBP to less than 90 mmHg and/or a decrease of DBP by at least 10 mmHg.
timeFrame: Week 9.
measure: Percentage of subjects showing a decrease in SBP to less than 130 mmHg and/or a decrease of SBP by at least 20 mmHg AND a decrease in DBP to less than 80 mmHg and/or a decrease of DBP by at least 10 mmHg.
timeFrame: Week 9.
measure: Change from Baseline in Pulse Rate at Week 9.
timeFrame: Baseline and Week 9.
measure: Change from Baseline in Systolic Blood Pressure at Final Visit.
timeFrame: Baseline and Final Visit (up to Week 9)
measure: Change in Baseline in Diastolic Blood Pressure at Final Visit.
timeFrame: Baseline and Final Visit (up to Week 9)
measure: Change from Baseline in Pulse Rate at Final Visit.
timeFrame: Baseline and Final Visit (up to Week 9)
Other outcomes:
Locations:
city: Berlin
country: Germany
city: Blankenhain
country: Germany
city: Dortmund
country: Germany
city: Hamburg
country: Germany
city: Köthen
country: Germany
city: Löhne
country: Germany
city: Nürnberg
country: Germany
city: Remscheid
country: Germany
city: Rodgau
country: Germany
city: Stockach
country: Germany
city: Wardenburg
country: Germany
city: Weinheim
country: Germany
city: Ivano-Frankivsk
country: Ukraine
city: Kharkiv
country: Ukraine
city: Kiev
country: Ukraine
city: Lviv
country: Ukraine
Study officials:
affiliation: Takeda Pharma GmbH (Germany)
name: Medical Director
role: STUDY_DIRECTOR
References: